+ Watch RPRX
on My Watchlist
A biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.
I'm looking for a short-term rebound in Repros as the company approaches completion of their ZP-204 study. also known as the Proellex Reanimation Study. Repros has signalled that they will conclude that Proellex can be advanced back into phase III trials for endometriosis once the FDA has signed off on the trial design, and I believe that that announcement will provide upward momentum from the current eroded share price. Meanwhile, topline data from three simultaneous phase II trials of Androxal is expected by the end of 2011 and I believe that the company will announce that the data supports an application to the FDA for an SPA for a phase III trial.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions